Rui-Ru Ji, PhD

Industry veteran with over 20 years of experience spanning all stages of R&D in immuno-oncology, oncology, immunology, infectious diseases, and neuroscience. Involved in development of 10 marketed medicines including COVID vaccine BNT162b2 and the first approved immune checkpoint inhibitor ipilimumab.